A 7-year analysis of PARTNER 3 showed that TAVR with the SAPIEN 3 valve matched surgical aortic-valve replacement in low-risk adults with severe aortic stenosis. Among 1,000 adults, the composite rate of death, stroke, or valve- or procedure-related rehospitalization was similar (34.6% vs 37.2%). Valve durability remained comparable, with failure occurring in 6.9% after TAVR and 7.3% after surgery. TAVR led to far less new-onset atrial fibrillation (17.7% vs 43.5%) but more left bundle branch block, valve thrombosis, pacemaker implantation, and paravalvular regurgitation. Funding and several disclosures involved Edwards Lifesciences.